5 July 2024 in Journal of Child and Adolescent Psychopharmacology
Objectives: Patterns of psychotropic medication use in children and adolescents with Down syndrome (DS) are largely unknown. Clinical decisions are often made from evidence and experience from individuals with autism spectrum disorder (ASD) or intellectual disability (ID). Methods: Longitudinal data from 670 children with DS who received care in a specialty DS clinic from March 2021 to February 2024 were collected. After each clinic visit, the clinician indicated the presence or absence of co-occurring neurodevelopmental (ND) or mental health (MH) diagnoses, as well as whether the individual was prescribed a psychopharmacological treatment. We used descriptive statistics and analyzed associations between psychotropic medication use, co-occurring ND/MH conditions, and demographic data. Results: 19.1% of patients were prescribed at least one psychotropic medication at their most recent clinical visit. Alpha-agonists were the most commonly prescribed medication class (30.8%), followed by stimulants (18.9%), and antidepressants (16.7%). There was a significant difference in psychotropic medication use by age, with older children having increased odds of being prescribed a psychotropic medication. There were no differences in psychotropic medication use across sex ( p = 0.10), race ( p = 0.10), or household income ( p = 0.16). Conclusions: We found that one-fifth of patients with DS were prescribed psychotropic medications. Nearly every individual with DS who was prescribed a psychotropic medication had a co-occurring ND/MH condition, yet these rates were lower than what have been reported in children with ID, ASD, and attention deficit/hyperactivity disorder. Further research needs to include those with DS to further understand medication efficacy and safe dosing practices to ensure optimal outcomes.
15 July 2025 in Journal of Intellectual Disability Research
20 December 2023 in Journal of Developmental & Behavioral Pediatrics
Objective: To describe the distribution of expressive language abilities of individuals with Down syndrome (DS) in a clinical sample and characterize demographic, environmental, and medical factors associated with varying expressive language profiles. Methods: Cross-sectional analysis was completed on a sample of 345 individuals with DS between the ages of 4 and 22 years who were enrolled into a longitudinal clinical database between March 2018 and August 2021. Expressive language-related items on a standardized caregiver-reported questionnaire assessing domains of functioning in neurodevelopmental disorders were used to conduct latent variable modeling and determine caregiver-reported expressive language (CREL) classes across the sample. Linear regression was used to explore associations between CREL classes and predictor variables. Results: Latent variable modeling revealed 3 distinct classes of CREL abilities representing higher, middle, and lower CREL. Individuals in the lower CREL class were more likely to be female, to use sign language or visual communication systems, have reduced pronunciation, attend private or residential school, and to be in a substantially separate classroom. Membership was not predicted by complex medical histories or co-occurring neurodevelopmental diagnoses. Conclusion: Caregiver-reported expressive language abilities in a cohort of individuals with DS were variable, with most of the individuals belonging to higher or middle CREL classes, relative to one another. Additional studies are indicated to understand factors that predict higher expressive language ability and explore how to direct services to individuals who are at risk of more profound language delays.
25 March 2026 in Annals of the Child Neurology Society
Objective: Children with Down syndrome follow distinct developmental trajectories that require specialized monitoring and counseling. We aimed to provide updated estimates of developmental milestone attainment using a nonparametric approach and to compare these results with previously reported generalized linear mixed‐effects model (GLMM) estimates. Methods: We reanalyzed developmental data from 842 children with Down syndrome (ages 2 months to 24 years). For each milestone, achievement rates were calculated within overlapping 0.5‐year time windows, and shape‐constrained additive models were used to derive monotonic regression curves. Results: Compared with GLMM‐based estimates, the nonparametric approach predicted milestone attainment at least 1 year earlier for 17 of 25 milestones at the highest comparable percentile. Early gross motor milestones showed consistent achievement patterns across methods, whereas more complex adaptive, language, and academic skills demonstrated greater variability and were more sensitive to modeling assumptions. Females achieved 17 of 25 milestones at least 1 year earlier than males. Conclusions: These findings highlight substantial developmental heterogeneity and support the potential for continued skill acquisition throughout childhood and adolescence in individuals with Down syndrome. The updated estimates provide clinically relevant reference points to guide individualized monitoring, anticipatory guidance, and family counseling.
19 October 2026 in Journal of Developmental & Behavioral Pediatrics
Objective: To examine the associations between medical conditions and early developmental skills in young children with Down syndrome (DS). Method: Data were drawn from the first timepoint of a longitudinal study of children with DS (n = 114; mean age = 20.6 months). Caregivers completed a comprehensive medical history questionnaire, followed by a structured interview and review by a medical doctor to clarify endorsed conditions. Cognitive, expressive, and receptive communication, and fine and gross motor developments were assessed using the Bayley Scales of Infant and Toddler Development, Fourth edition. Associations between medical condition categories and developmental skills across domains were examined using partial correlations adjusting for age. Dominance analyses assessed the unique contributions of significant medical categories. Results: Vision conditions were associated with lower developmental scores across cognitive, communication, and gross motor domains. Seizure/epilepsy was associated with lower cognitive, expressive communication, and motor domain scores. Length of neonatal intensive care unit stay was associated with lower cognitive and communication scores. Additional factors, including premature birth, structural gastrointestinal conditions, dysphagia, eczema, and thyroid disease, were associated with lower scores in specific developmental domains. Dominance analyses revealed overlapping contributions across significant predictors with each developmental domain. Conclusion: Findings highlight the associations between co-occurring medical conditions and developmental heterogeneity among young children with DS. Results underscore the need for further work, including longitudinal research studies, to clarify the role of medical conditions in shaping neurodevelopment in DS.